144875-48-9 | Resiquimod

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$10.00	$7.00
25mg	≥ 98%	in stock	$98.00	$69.00
100mg	98%	in stock	$101.00	$71.00
250mg	98%	in stock	$183.00	$128.00
500mg	97%	in stock	$330.00	$231.00
1g	≥98%	in stock	$415.00	$290.00
5g	98%	in stock	$1,329.00	$931.00

Description

• Catalog Number: AA72740
• Chemical Name: Resiquimod
• CAS Number: 144875-48-9
• Molecular Formula: C17H22N4O2
• Molecular Weight: 314.3822
• MDL Number: MFCD00937759
• SMILES: CCOCc1nc2c(n1CC(O)(C)C)c1ccccc1nc2N

Computed Properties

• Complexity: 406
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 1.3

Literature

• Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach.

  Toxicology and applied pharmacology 20180101

• IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.

  The Journal of biological chemistry 20171110

• Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.

  Blood 20130418

• A critical role for MAPK signalling pathways in the transcriptional regulation of toll like receptors.

  PloS one 20130101

• Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human haematopoietic cells of myeloid lineage.

  The international journal of biochemistry & cell biology 20121101

• Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

  Journal of clinical immunology 20121001

• Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

  Biomaterials 20120601

• TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen.

  Journal of immunology (Baltimore, Md. : 1950) 20120515

• R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts.

  Cytotechnology 20120501

• Bacterial immunotherapy of gastrointestinal tumors.

  Langenbeck's archives of surgery 20120401

• MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.

  Journal of immunology (Baltimore, Md. : 1950) 20120401

• Characterisation and expression analysis of the Atlantic halibut (Hippoglossus hippoglossus L.) cytokines: IL-1β, IL-6, IL-11, IL-12β and IFNγ.

  Molecular biology reports 20120301

• R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes.

  BMC infectious diseases 20120101

• Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development.

  Journal of biomedicine & biotechnology 20120101

• Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system.

  Frontiers in physiology 20120101

• Uterine epithelial cells specifically induce interferon-stimulated genes in response to polyinosinic-polycytidylic acid independently of estradiol.

  PloS one 20120101

• High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.

  PloS one 20120101

• Vaccine Development Against Leishmania donovani.

  Frontiers in immunology 20120101

• Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms.

  Frontiers in physiology 20120101

• Adjuvants for Leishmania vaccines: from models to clinical application.

  Frontiers in immunology 20120101

• Plasmacytoid dendritic cell interferon-α production to R-848 stimulation is decreased in male infants.

  BMC immunology 20120101

• Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

  Journal of immunological methods 20111028

• The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation.

  Veterinary immunology and immunopathology 20111015

• Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110715

• Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms.

  European journal of immunology 20110701

• Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4.

  Arthritis and rheumatism 20110601

• CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

  Expert review of vaccines 20110601

• Pattern recognition receptors and the innate immune response to viral infection.

  Viruses 20110601

• Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.

  Blood 20110526

• Targeting the Toll-like receptor 7 pathway in asthma: a potential immunomodulatory approach?

  Expert opinion on therapeutic targets 20110501

• Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

  Acta pharmacologica Sinica 20110501

• Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.

  Journal of immunology (Baltimore, Md. : 1950) 20110415

• Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.

  Journal of immunology (Baltimore, Md. : 1950) 20110401

• A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

  Journal of immunology (Baltimore, Md. : 1950) 20110401

• Stimulation of TLR7 prior to polymicrobial sepsis improves the immune control of the inflammatory response in adult mice.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20110301

• The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation.

  PLoS pathogens 20110301

• Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle.

  European journal of pharmacology 20110210

• Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1β.

  Cellular and molecular life sciences : CMLS 20110101

• Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

  Cancer immunology, immunotherapy : CII 20110101

• The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma.

  Journal of immunology (Baltimore, Md. : 1950) 20110101

• TLR3 and TLR7 modulate IgE production in antigen induced pulmonary inflammation via influencing IL-4 expression in immune organs.

  PloS one 20110101

• Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes.

  Clinical & developmental immunology 20110101

• Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

  PloS one 20110101

• Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells.

  PloS one 20110101

• The transcriptome of Trichuris suis--first molecular insights into a parasite with curative properties for key immune diseases of humans.

  PloS one 20110101

• The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.

  Cellular immunology 20110101

• A common path to innate immunity to HIV-1 induced by Toll-like receptor ligands in primary human macrophages.

  PloS one 20110101

• Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.

  Journal of translational medicine 20110101

• Comparative analysis of species-specific ligand recognition in Toll-like receptor 8 signaling: a hypothesis.

  PloS one 20110101

• Toll-like receptors and myocardial inflammation.

  International journal of inflammation 20110101

• Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines.

  Clinical & developmental immunology 20110101

• Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.

  PloS one 20110101

• Signatures of positive selection in Toll-like receptor (TLR) genes in mammals.

  BMC evolutionary biology 20110101

• The combination of early and rapid type I IFN, IL-1α, and IL-1β production are essential mediators of RNA-like adjuvant driven CD4+ Th1 responses.

  PloS one 20110101

• Predicting antitumor activity of peptides by consensus of regression models trained on a small data sample.

  International journal of molecular sciences 20110101

• An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

  Clinical and vaccine immunology : CVI 20101201

• Exhaustive exercise reduces TNF-α and IFN-α production in response to R-848 via toll-like receptor 7 in mice.

  European journal of applied physiology 20101101

• Inhibition of the type I interferon antiviral response during arenavirus infection.

  Viruses 20101101

• Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20100901

• TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.

  Vaccine 20100831

• 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated suppression of toll-like receptor stimulated B-lymphocyte activation and initiation of plasmacytic differentiation.

  Toxicological sciences : an official journal of the Society of Toxicology 20100701

• Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers.

  Clinical and vaccine immunology : CVI 20100701

• Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options.

  International journal of dermatology 20100701

• Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.

  Journal of medicinal chemistry 20100408

• Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

  Blood 20100311

• The role of redox-dependent mechanisms in the downregulation of ligand-induced Toll-like receptors 7, 8 and 4-mediated HIF-1 alpha prolyl hydroxylation.

  Immunology and cell biology 20100201

• The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.

  Cancer immunology, immunotherapy : CII 20100101

• Topical resiquimod: a promising adjuvant for vaccine development?

  Expert review of vaccines 20100101

• Toll-like receptor-mediated recognition of herpes simplex virus.

  Frontiers in bioscience (Scholar edition) 20100101

• Molecular modulation of intestinal epithelial barrier: contribution of microbiota.

  Journal of biomedicine & biotechnology 20100101

• Immune mechanisms of protection: can adjuvants rise to the challenge?

  BMC biology 20100101

• Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice.

  PloS one 20100101

• Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists.

  PloS one 20100101

• Toll-like receptors: role in dermatological disease.

  Mediators of inflammation 20100101

• Targeting Toll-like receptors for treatment of SLE.

  Mediators of inflammation 20100101

• Cellular and molecular mechanisms underlying the strong neonatal IL-12 response of lamb mesenteric lymph node cells to R-848.

  PloS one 20100101

• Tetra-O-methyl nordihydroguaiaretic acid (Terameprocol) inhibits the NF-κB-dependent transcription of TNF-α and MCP-1/CCL2 genes by preventing RelA from binding its cognate sites on DNA.

  Journal of inflammation (London, England) 20100101

• Pharmacotherapy of actinic keratosis.

  Expert opinion on pharmacotherapy 20091201

• Topical resiquimod promotes priming of CTL to parenteral antigens.

  Vaccine 20090925

• Modulation of the allergic asthma transcriptome following resiquimod treatment.

  Physiological genomics 20090807

• Flow cytometric investigation of neutrophil oxidative burst and apoptosis in physiological and pathological situations.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20090601

• Do postsurgical interventions optimize ultimate scar cosmesis.

  Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 20090601

• TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

  Vaccine 20090518

• 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.

  Bioorganic & medicinal chemistry letters 20090415

• Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.

  Vaccine 20090414

• Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

  Journal of immunology (Baltimore, Md. : 1950) 20090301

• Expression and activity of Toll-like receptors 1-9 in the human term placenta and changes associated with labor at term.

  Biology of reproduction 20090201

• Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production.

  The Journal of allergy and clinical immunology 20090101

• Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1.

  PloS one 20090101

• TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells.

  Immunobiology 20090101

• Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects.

  Respiratory research 20090101

• Sequence determinants of innate immune activation by short interfering RNAs.

  BMC immunology 20090101

• Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

  PloS one 20090101

• Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

  BMC cancer 20090101

• Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.

  PloS one 20090101

• Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

  Journal of translational medicine 20090101

• Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

  Cancer immunology, immunotherapy : CII 20081101

• Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.

  Experimental biology and medicine (Maywood, N.J.) 20080801

• A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.

  The British journal of dermatology 20080701

• Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells.

  The Journal of experimental medicine 20080609

• Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma).

  Journal of leukocyte biology 20080401

• Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice.

  Biochemical and biophysical research communications 20080307

• TLR7 and TLR8 as targets in cancer therapy.

  Oncogene 20080107

• Comparison of human B cell activation by TLR7 and TLR9 agonists.

  BMC immunology 20080101

• Toll-like receptors and viruses: induction of innate antiviral immune responses.

  The open microbiology journal 20080101

• Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.

  The Journal of biological chemistry 20071221

• TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response.

  European journal of immunology 20071001

• Resiquimod and other immune response modifiers as vaccine adjuvants.

  Expert review of vaccines 20071001

• Impaired CCR7 expression on plasmacytoid dendritic cells of HIV-infected children and adolescents with immunologic and virologic failure.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.

  Journal of hepatology 20070801

• The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070501

• Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.

  The Journal of infectious diseases 20070501

• Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.

  Journal of immunology (Baltimore, Md. : 1950) 20070401

• Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects.

  Journal of molecular biology 20070105

• TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation.

  Journal of leukocyte biology 20070101

• Therapeutic use of Aldara in chronic myeloid leukemia.

  Journal of translational medicine 20070101

• Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.

  Journal of translational medicine 20070101

• Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

  Journal of translational medicine 20070101

• Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

  Journal of translational medicine 20070101

• Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

  BMC immunology 20070101

• HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts.

  PloS one 20070101

• Primary prevention of allergic diseases: current concepts and mechanisms.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101

• Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20061201

• A distinct subset of intestinal dendritic cells responds selectively to oral TLR7/8 stimulation.

  European journal of immunology 20061001

• Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling.

  The Journal of biological chemistry 20060915

• Toll-like receptor priming sensitizes macrophages to proinflammatory cytokine gene induction by deoxynivalenol and other toxicants.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages.

  FEMS immunology and medical microbiology 20060801

• Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.

  European journal of immunology 20060701

• Toll-like receptors mediate proliferation and survival of multiple myeloma cells.

  Leukemia 20060601

• [Application of imiquimod and resiquimod in dermatology].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20060601

• TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.

  American journal of physiology. Lung cellular and molecular physiology 20060501

• Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7/8 ligand.

  Journal of immunology (Baltimore, Md. : 1950) 20060501

• Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.

  Journal of medicinal chemistry 20060323

• Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3.

  Nature 20060309

• Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

  Antiviral research 20060201

• New approaches to vaccine adjuvants: inhibiting the inhibitor.

  PLoS medicine 20060101

• The role of topical immune response modifiers in skin cancer.

  Drugs 20060101

• Innate immunity for biodefense: a strategy whose time has come.

  The Journal of allergy and clinical immunology 20051201

• TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

  Vaccine 20051101

• TLR and NOD2 ligands induce cell proliferation in the rat intact spinal cord.

  Journal of neuropathology and experimental neurology 20051101

• Microglia activation in rat spinal cord by systemic injection of TLR3 and TLR7/8 agonists.

  Journal of neuroimmunology 20050701

• A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

  The Journal of experimental medicine 20050502

• Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

  Journal of immunology (Baltimore, Md. : 1950) 20050401

• Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens.

  Immunology 20050401

• Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes.

  Immunology 20050401

• Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

  Journal of immunology (Baltimore, Md. : 1950) 20050201

• Toll-like receptor downstream signaling.

  Arthritis research & therapy 20050101

• Generation and maturation of dendritic cells for clinical application under serum-free conditions.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20050101

• Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.

  Antiviral research 20041101

• Emerging therapies for herpes viral infections (types 1 - 8).

  Expert opinion on emerging drugs 20041101

• Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

  Journal of immunology (Baltimore, Md. : 1950) 20041001

• Topical immunomodulation in dermatology: potential of toll-like receptor agonists.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20040801

• Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20040801

• Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors.

  Journal of immunology (Baltimore, Md. : 1950) 20040615

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.

  The Journal of investigative dermatology 20040501

• Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.

  Apoptosis : an international journal on programmed cell death 20040501

• Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.

  Vaccine 20040416

• Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.

  Vaccine 20040416

• Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival.

  Journal of immunology (Baltimore, Md. : 1950) 20040415

• The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.

  European journal of immunology 20031101

• Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures.

  The British journal of dermatology 20031101

• Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.

  Journal of immunology (Baltimore, Md. : 1950) 20031015

• Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.

  Journal of the National Cancer Institute 20030806

• An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.

  The American journal of pathology 20030801

• [Topical immunomodulators in dermatology].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20030701

• The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

  The Journal of allergy and clinical immunology 20030201

• Resiquimod 3M.

  Current opinion in investigational drugs (London, England : 2000) 20030201

• Recurrent genital herpes treatments and their impact on quality of life.

  PharmacoEconomics 20030101

• [Imiquimod and resiquimod. The onset of a new pharmaco-therapeutic class?].

  Annales de dermatologie et de venereologie 20030101

• Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors.

  The Journal of investigative dermatology 20021101

• Current treatments and perceptions of genital herpes: a European-wide view.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20021101

• Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.

  Nature immunology 20020601

• The clinical management of recurrent genital herpes: current issues and future prospects.

  Herpes : the journal of the IHMF 20020401

• Herpes simplex viruses 1 and 2.

  Dermatologic clinics 20020401

• Immunomodulation as a treatment strategy for genital herpes: review of the evidence.

  International immunopharmacology 20020301

• Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

  Nature immunology 20020201

• Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

  Cellular immunology 20020101

• Imiquimod and resiquimod as novel immunomodulators.

  The Journal of antimicrobial chemotherapy 20011201

• Topical immunomodulators--progress towards treating inflammation, infection, and cancer.

  The Lancet. Infectious diseases 20011001

• Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study.

  The Journal of infectious diseases 20010715

• Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

  The Journal of infectious diseases 20010315

• The immune response modifier resiquimod mimics CD40-induced B cell activation.

  Cellular immunology 20010225

• Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

  Antiviral research 19951101

• Editorials: More health care with less.

  Dimensions in health service 19751201